Jazz Pharmaceuticals plc - Laporan Laba Rugi (TTM)

Jazz Pharmaceuticals plc
CH ˙ BRSE ˙ IE00B4Q5ZN47
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Jazz Pharmaceuticals plc menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,280 2,364 2,436 2,626 2,863 3,094 3,300 3,481 3,584 3,659 3,738 3,763 3,794 3,834 3,843 3,910 3,993 4,069 4,065 4,087
Change (%) 3.67 3.08 7.77 9.03 8.08 6.66 5.49 2.95 2.10 2.16 0.65 0.84 1.05 0.24 1.73 2.12 1.91 -0.10 0.54
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 134 149 160 186 206 218 229 232 232 267 284 298 306 284 282 289 295 311 319 321
Change (%) 11.04 7.74 15.70 11.03 5.60 5.12 1.19 0.05 15.30 6.31 4.86 2.90 -7.27 -0.58 2.46 1.81 5.44 2.64 0.78
% of Revenue 5.88 6.30 6.59 7.07 7.20 7.03 6.93 6.65 6.46 7.30 7.60 7.91 8.08 7.41 7.35 7.40 7.38 7.64 7.85 7.86
Gross Operating Profit 2,146 2,215 2,276 2,440 2,657 2,877 3,072 3,250 3,352 3,392 3,454 3,465 3,488 3,550 3,561 3,620 3,698 3,758 3,746 3,765
Change (%) 3.21 2.77 7.21 8.88 8.27 6.78 5.81 3.15 1.19 1.83 0.31 0.66 1.78 0.30 1.67 2.14 1.63 -0.33 0.52
% of Revenue 94.12 93.70 93.41 92.93 92.80 92.97 93.07 93.35 93.54 92.70 92.40 92.09 91.92 92.59 92.65 92.60 92.62 92.36 92.15 92.14
SG&A 846 880 926 1,170 1,326 1,399 1,291 1,222 1,276 1,399 1,397 1,378 1,269 1,307 1,361 1,359 1,376 1,416 1,578 1,426
Change (%) 3.97 5.24 26.31 13.37 5.52 -7.75 -5.33 4.42 9.61 -0.09 -1.38 -7.94 3.05 4.12 -0.17 1.29 2.88 11.46 -9.64
% of Revenue 37.12 37.23 38.00 44.54 46.31 45.22 39.11 35.10 35.60 38.22 37.37 36.62 33.43 34.09 35.41 34.75 34.47 34.79 38.82 34.89
R&D 316 310 306 354 416 476 530 536 532 555 615 685 782 824 857 869 834 854 811 781
Change (%) -2.02 -1.14 15.60 17.62 14.39 11.21 1.20 -0.76 4.39 10.70 11.42 14.22 5.30 4.06 1.34 -3.97 2.30 -4.94 -3.79
% of Revenue 13.87 13.11 12.57 13.48 14.54 15.39 16.05 15.40 14.84 15.18 16.45 18.20 20.62 21.49 22.31 22.22 20.90 20.98 19.96 19.10
OpEx 1,662 1,598 1,658 2,052 2,384 2,619 2,679 2,627 2,659 2,820 2,873 2,941 2,952 3,023 3,115 3,134 3,125 3,207 3,334 3,161
Change (%) -3.87 3.72 23.78 16.20 9.85 2.29 -1.93 1.20 6.07 1.87 2.38 0.35 2.44 3.03 0.62 -0.29 2.63 3.96 -5.20
% of Revenue 72.92 67.61 68.03 78.13 83.27 84.64 81.17 75.46 74.18 77.07 76.85 78.16 77.79 78.86 81.05 80.16 78.27 78.82 82.03 77.34
Operating Income 617 765 779 574 479 475 621 854 925 839 866 822 843 811 728 776 868 862 730 926
Change (%) 24.00 1.75 -26.29 -16.58 -0.77 30.74 37.48 8.32 -9.31 3.15 -5.06 2.57 -3.82 -10.16 6.49 11.87 -0.69 -15.22 26.75
% of Revenue 27.08 32.39 31.97 21.87 16.73 15.36 18.83 24.54 25.82 22.93 23.15 21.84 22.21 21.14 18.95 19.84 21.73 21.18 17.97 22.66
Interest Expense -90 -111 -109 -152 -218 -281 -324 -319 -309 -300 -303 -338 -345 -355 -347 -358 -352 -344 -332 -316
Change (%) 22.60 -2.00 39.79 43.44 28.85 15.44 -1.65 -3.02 -2.97 1.16 11.44 2.03 2.84 -2.27 3.42 -1.64 -2.29 -3.60 -4.96
% of Revenue -3.96 -4.69 -4.46 -5.78 -7.61 -9.07 -9.81 -9.15 -8.62 -8.19 -8.11 -8.98 -9.09 -9.25 -9.02 -9.17 -8.83 -8.46 -8.17 -7.72
Net Income 179 239 518 40 -161 -330 -450 -52 -19 -224 -156 -87 80 415 331 395 463 560 482 -405
Change (%) 33.16 117.20 -92.25 -500.61 104.89 36.46 -88.47 -63.97 1,099.02 -30.25 -44.64 -192.42 418.84 -20.26 19.39 17.28 20.93 -13.91 -183.96
% of Revenue 7.86 10.10 21.27 1.53 -5.62 -10.65 -13.63 -1.49 -0.52 -6.12 -4.18 -2.30 2.11 10.82 8.61 10.10 11.60 13.77 11.86 -9.91

Source: Capital IQ

Other Listings
IT:1JAZZ € 102.75
DE:J7Z € 110.35
US:JAZZ US$ 129.50
MX:JAZZ N
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista